FluoGuide (FLOU) Q3 2024 earnings summary

Executive summary

• FG001, FluoGuide's lead product, demonstrated positive phase II results in both brain and head and neck cancers, lighting up cancer in all patients in recent trials.

• Clinical trial application for FG001 in head and neck cancer was submitted, marking a key milestone toward regulatory approval.

• Focus remains on late-stage clinical development and commercialization, with additional regulatory and medical expertise added to the team.

• FG002 development is on hold to concentrate resources on FG001 due to strong clinical outcomes.

Financial highlights

• No revenue reported for Q3 2024 or year-to-date; net loss for Q3 2024 was DKK 5,495 thousand, improved from DKK 9,315 thousand in Q3 2023.

• Year-to-date net loss was DKK 20,218 thousand, compared to DKK 25,990 thousand for the same period last year.

• Cash and bank position at September 30, 2024, was DKK 20,157 thousand, up from DKK 8,945 thousand a year earlier.

• Solvency ratio increased to 90% from 73% year-over-year.

• Result per share for Q3 2024 was DKK -0.40, compared to DKK -0.78 in Q3 2023.

Outlook and guidance

• 2025 milestones include regulatory evaluation with FDA for FG001 in brain cancer, submission of new clinical trial applications, and interim data from ongoing trials.

• Plans to expand FG001 indications to additional brain tumors and head and neck cancers, and to develop its use as a photosensitizer.

• Targeting new partnerships and advancing collaboration with Intuitive Surgical.

• Long-term objectives include first approvals in the US and head and neck cancer markets, and broadening FG001's market potential.